On March 30, China National Medical Device Co., Ltd. (CNMD for short) under Sinopharm Group and Suzhou Hybiome Biomedical Engineering Co. Ltd., subsidiary of BioMerieux in China held a signing ceremony of the strategic cooperation agreement. This is another breakthrough of CNMD in the field of in vitro diagnostic products (IVD) after the successful implementation of the orthopedic equipment integration project of CNMD in 2021. The partner selected by CNMD this time is Hybiome, which focuses on the production of chemiluminescence immunodiagnostic products.

At present, in the field of immunodiagnosis dominated by chemiluminescence, the market scale is more than 30 billion CNY, which is also one of the largest market segments in the field of IVD. However, due to the late introduction of technology and high technical barriers, it is still monopolized by imported brands. Among them, the overall market share of foreign brands represented by "Roche, Abbott, Beckman Coulter and Siemens" is nearly 80%, while the market share of a single domestic enterprise is no more than 5%. How to deal with the future national IVD volume procurement and the reshaping of industry rules? Under this opportunity, the integrated marketing strategy of CNMD undoubtedly provides clear cooperation solutions for all parties.

About CNMD:

China National Medical Devices Co., Ltd., a subsidiary of Sinopharm Group, is the only enterprise that focuses on the operation of medical devices. It has long undertaken the task of central reserve of national medical assistance materials. It has a nationwide medical device business network and medical device logistics network, seven large-scale regional logistics centers, more than 40 provincial logistics centers and more than 200 grass-roots logistics centers, directly serving nearly 10000 ending customers.

About Hybiome:

Suzhou Hybiome Biomedical Engineering Co. Ltd. is a high-tech enterprise focused on R&D, production, and distribution of in vitro diagnostic products. The main products include automated chemiluminescence immunoassay (CLIA) analyzers and reagents. It was also the first Chinese CFDA approved provider of automatic blood grouping analyzers for microcolumn gel card; a blood grouping technology.

The company actively promoting exchanges and cooperation with domestic and overseas scientific institutes, and are dedicated to provide the market with High-quality IVD products for clinical diagnosis. It believes that Hybiome will become the domestic leading enterprise in the IVD industry within a few years. On Nov. 2018, the company has been acquired by BioMerieux.